Updates are available Correction dated 2022-10-13
Click to view Correction: https://doi.org/10.1038/s41467-022-33878-6
-
Authors
Liu, Yang
Zhang, Xianwen
Liu, Jianying
Xia, Hongjie https://orcid.org/0000-0002-2520-7038
Zou, Jing
Muruato, Antonio E.
Periasamy, Sivakumar https://orcid.org/0000-0002-7038-5140
Kurhade, Chaitanya
Plante, Jessica A. https://orcid.org/0000-0002-4768-7458
Bopp, Nathen E.
Kalveram, Birte
Bukreyev, Alexander https://orcid.org/0000-0002-0342-4824
Ren, Ping https://orcid.org/0000-0002-4022-6667
Wang, Tian https://orcid.org/0000-0002-1511-0793
Menachery, Vineet D. https://orcid.org/0000-0001-8803-7606
Plante, Kenneth S. https://orcid.org/0000-0002-7485-3167
Xie, Xuping https://orcid.org/0000-0003-0918-016X
Weaver, Scott C. https://orcid.org/0000-0001-8016-8556
Shi, Pei-Yong https://orcid.org/0000-0001-5553-1616
- License Information
-
More Information
Article History
Received: 11 February 2022
Accepted: 8 July 2022
First Online: 27 July 2022
Change Date: 13 October 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-022-33878-6
Competing interests
: The Shi laboratory has received funding support in sponsored research agreements from Pfizer, Gilead, Novartis, GSK, Merck, IGM Biosciences, and Atea Pharmaceuticals. P.Y.S. is a member of the Pfizer COVID Antiviral Medical Board, a member of the Scientific Advisory Board of AbImmune, and a founder of FlaviTech. The remaining authors declare no competing interests.
